1-3 of 3
James A. Zwiebel, MD
Close
Sort by
Journal Articles

A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).

Karen W.L. Yee, MD, Mark D. Minden, MD, Joseph Brandwein, MD, Aaron Schimmer, MD, Andre Schuh, MD, Vikas Gupta, MD, Hans A. Messner, MD, Ronan Foley, MD, Parveen Wasi, MD, James A. Zwiebel, MD, Brian Leber, MD
Journal: Blood
Blood (2007) 110 (11): 908.
https://doi.org/10.1182/blood.V110.11.908.908
Published: 2007
Journal Articles

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Steven D. Gore, MD, Anchalee Jiemjit, MS, Lewis B. Silverman, MD, Timothy Aucott, Stephen Baylin, MD, Hetty Carraway, MD, Tianna Dauses, BSN, Tamer Fandy, PhD, James Herman, MD, Judith E. Karp, MD, Jonathan D. Licht, MD, Anthony J. Murgo, MD, Rosalie Odchimar-Reissig, BSN, B. Douglas Smith, MD, James A. Zwiebel, MD, Elizabeth Sugar, PhD
Journal: Blood
Blood (2006) 108 (11): 517.
https://doi.org/10.1182/blood.V108.11.517.517
Published: 2006
Journal Articles

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Steven D. Gore, MD, Stephen B. Baylin, MD, Tianna Dauses, RN, Michael R. Grever, MD, Anchalee Jiemjit, MS, Jasper Manning, MS, Carole B. Miller, MD, Anthony J. Murgo, MD, James A. Zwiebel, MD, James G. Herman, MD
Journal: Blood
Blood (2004) 104 (11): 469.
https://doi.org/10.1182/blood.V104.11.469.469
Published: 2004